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Abstract 
Review on CPM, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
HGNC (Hugo): CPM 
Location: 12q15 
Note 
CPM was mapped to chromosome 12q13-qter by 
chromosome assignment in somatic cell hybrids. 
Fluorescent in situ hybridisation located CPM distal to 
D12S375 and proximal to the D12S8 microsatellite 
markers. After completion of the reference sequence of 
chromosome 12, CPM was located in 12q14.3. 
DNA/RNA 
Description 
The intron/exon structure of the CPM gene was 
determined from screening human kidney and placenta 
cDNA libraries (Bektas et al., 2001). The CPM gene 
contains 11 exons and spans 112.5 kb. The coding 
region is located in exons 2-9. 
Transcription 
Transcription is initiated from multiple transcription 
start sites clustered in two distinct regions that are 
flanked by two independent, functional promoters. The 
proximal promoter (~ 350 bp upstream of the coding 
region) is characterized by the presence of CpG islands, 
a classical TATA box (25 bp upstream of the major 
initiation site), an initiator sequence (Inr) around the 
TATA box, and a putative downstream promoter  
element (DPE). A number of potential transcription 
factor binding sites were identified in the 5' region 
flanking the proximal initiation sites, including a 
vitamin D3 responsive element and Sp1. The distal 
promoter (~ 30 kb upstream of the coding region) 
differs from the proximal promoter in that it mainly 
consists of repetitive elements and lacks common 
promoter elements. Inr sequences and a putative DPE 
were found together with putative Ets, C/EBP, Oct-1, 
AP-1 and NF-kB sites. Basal transcriptional activity of 
the proximal and distal promoter regions was cell type-
dependent pointing towards a tissue-specific expression 
of CPM. Transcriptional initiation from the distal start 
site appeared less common (Li et al., 2002). 
Apart from the full length CPM mRNA, three 
alternatively splice variants of CPM were detected. 
Missing exon 3 and/or 5, these products lead to a 
premature stop codon and possibly to the generation of 
truncated CPM proteins (Pessoa et al., 2002). Several 
bands ranging from about 2.4 kb to 15 kb were detected 
in Northern blots of CPM mRNA from various human 
tissues, with a major band at 4.2 kb (Tan et al., 1989; 
Nagae et al., 1993). Heterogeneity in the CPM mRNA 
was observed, principally ensuing from the 3' region. 
Together with alternative splicing of three separate 
exons (1, 1A and 1B), the utilization of various 
transcription start sites contributes to heterogeneity at 
the 5' region. 5' and 3' heterogeneity however did not 
change the CPM protein sequence (Li et al., 2002). 
The Ensemble database (viewed June 2013) lists 13 
transcripts for CPM of which 3 are coding for the full-
length protein and 4 are coding for shorter forms. Of 
the remainder, there is 1 non-coding processed 
transcript, 3 are labelled non-sense mediated decay and 
2 have a retained intron. 
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The 12q14-15 chromosomal region contains some known oncogenes and genes involved in cell cycle control, differentiation, 
receptor signalling and cytokine biology, as well as some miRNAs. The names of those genes are placed in boxes. The 
approximate length and positions of the genes on the + (right) and - (left) strands are depicted as grey blocks. Pseudogenes and 
uncharacterized loci are not shown. The information was retrieved from the Gene data bank (NCBI). The expanded region illustrates how 




CPM is a basic metallo-carboxypeptidase. The NC-
IUBMB code assigned to CPM is EC 3.4.17.12. In the 
MEROPS database CPM belongs to clan MC, family 
M14, subfamily B. 
Description 
The CPM structure consists of two domains, the 
classical carboxypeptidase domain and the C- 
terminal domain. The spherical carboxypeptidase 
domain (first 295 amino acids) is arranged in a typical 
α/β hydrolase fold and carries the catalytic site. A 
funnel-shaped entrance gives access to the active site. 
The C-terminal domain (86 residues) consists of a 
seven-stranded β-barrel and resembles the plasma 
protein transthyretin/prealbumin (Reverter et al., 2004). 
CPM is attached to the outer membrane by a glycosyl-
phosphatidyl-inositol (GPI) anchor located at the C-
terminus (Deddish et al., 1990). 
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The coding region of CPM is depicted by alternating blue en black letters to highlight the exon junctions (exon 2 to 9). The translated 
amino acid sequence is shown above the nucleotide sequence. The secretion signal peptide is shown in italics, the Zn2+ ligands in bold. 
Amino acids located in α-helices are highlighted in red and the β-sheets in yellow. 
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The 3D-structure of CPM was determined by X-ray 
crystallography (Reverter et al., 2004). It is shown in this figure 
as a ribbon drawing with α-helices and β-strands respectively 
shown in orange and blue, and the residual chain in grey. The 
catalytic carboxypeptidase domain is shown on top and the 
cup-shaped C-terminal domain on bottom of the structure. The 
disordered linker connecting the C-terminal domain and the 
GPI-anchoring segment is not visible in the structure. The 
catalytic zinc ion is depicted as a pink sphere, whereas the 
three zinc ligands are shown in dark blue. The cysteine 
residues involved in disulfide bridges are depicted in red. PDB-
code: 1UWY. Drawn with MOE 2009.10. 
Expression 
CPM is widely expressed in the different organs, but 
expression levels vary and it is only expressed by 
certain cell types. Expression was studied in some 
detail in the lung, in the female reproductive system, 
and in the kidney. 
In the lung CPM is a marker of type I pulmonary 
alveolar epithelial cells (Nagae et al., 1993). 
CPM expression is locally regulated during the 
different phases of the menstrual cycle, endometrial 
maturation and implantation. Overall, CPM is likely 
involved in the control of proliferation and functional 
differentiation of many cellular system within the 
female reproductive system (Yoshioka et al., 1998; 
Fujiwara et al., 1999; Fujiwara et al., 2005; Nishioka et 
al., 2003). 
In the kidney, CPM expression is high at the apical 
surface of proximal and distal tubuli and the thick 
ascending limbs of the loop of Henle. Soluble CPM 
was detected in the tubular lumina. CPM was also 
expressed at the parietal epithelium beneath the 
Bowman's basement membrane and in glomerular 
mesangial cells (Denis et al., 2013). 
In the central and peripheral nervous systems CPM  
expression is associated with myelin and myelin-
forming cells (Nagae et al., 1992; Kang et al., 2011). 
A soluble form of CPM, lacking the membrane anchor, 
was found in urine, amnion and seminal fluid and in 
broncho-alveolar lavage fluid. 
CPM was at least twice discovered as the target of 
antibodies raised against cell surface antigens: once on 
mature macrophages and once on the human B-lineage 
acute lymphoblastic leukemia cell line Pre ALP. 
Expression of CPM was reported in late stages of 
myeloid cell development and in particular stages of B 
lymphocyte development, i.e. committed precursors 
and germinal center cells. The expression of CPM in 
different stages of hematopoietic stem cell 
differentiation was comprehensively reviewed 
(Deiteren et al., 2009; Denis et al., 2012).  
The reader is referred to the publications listed in these 
reviews; some highlights are repeated below. CPM 
expression was evident in hematopoietic progenitors 
(CFU-GM, CFU-Meg and BFU-E). The surface 
expression of CPM was upregulated during ex vivo 
expansion of cord blood CD34+ stem cells to CFU-GM 
and CFU-Meg (Marquez-Curtis et al., 2008). 
CPM expression is weak on freshly isolated blood 
monocytes. In contrast to macrophages maturated in 
vitro, macrophages of body fluids (pleural, peritoneal 
and alveolar) and tissue macrophages in situ express 
only low levels of CPM. In defined pathological 
conditions, some exudate macrophages did express 
considerable levels of CPM, e.g. alveolar macrophages. 
Inflammatory macrophages in situ were CPM negative 
except those associated with rejected renal allografts 
(Andreesen et al., 1988). CPM is expressed selectively 
in tissue granulomas and foam cells (Tsakiris et al., 
2012) and on tumor associated macrophages (Denis et 
al., 2013; Tsakiris et al., 2008). Peripheral granulocytes 
all possessed CPM surface expression. The expression 
of CPM on several immortalized cell lines was 
reviewed (Denis and Lambeir, 2013). THP-1 cells, that 
are close to the mature macrophage, express high levels 
of CPM. 
CPM expression was observed early in mesenchymal 
differentiation, i.e. in mesenchymal stem cells (MSC) 
and CFU-F progenitor cells (Marques-Curtis et al., 
2008). CPM was upregulated in early and late stages of 
bone marrow or adipose tissue derived MSC 
differentiation into the osteogenic, chondrogenic and 
adipogenic lineages (Lui at al., 2007). CPM expression 
was greatly increased in early and late stadia of MSC 
differentiation into the adipocyte and osteogenic 
lineage compared to the chondrogenic lineage. 
Differential transcript analysis identified CPM as a 
surface marker of heterogeneous peripheral blood-
derived smooth muscle progenitor cells (Wang et al., 
2012). 
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Localisation 
The GPI anchor directs CPM to lipid rafts in the outer 
membrane of cells, such as macrophages. In the kidney 
CPM is found in the lumen and on the luminal side of 
epithelial cells in proximal and distal tubules.  
Intracellular CPM immunoreactivity was also observed 
(Denis et al., 2013). 
Function 
The function of CPM in the different cells and organs is 
not well understood. The expression pattern of CPM in 
specific cells in the different systems suggests roles in 
development and/or differentiation.  
On the one hand CPM may be important for the 
recycling of amino acids or the local release of 
arginine.  
On the other hand, CPM may function by modulating 
signaling cascades of its substrates (Deiteren et al., 
2009). The classical substrates for CPM are 
anaphylatoxins and kinins, produced during 
inflammation. However, many other potential 
substrates have been identified, including hormones, 
chemokines and growth factors. A functional 
association of CPM with the bradykinin-1 receptor (a 
G-protein coupled receptor) has been demonstrated 
(Zhang et al., 2008; Zhang et al., 2011). CPM enhances 
bradykinin-1 receptor signaling on two levels: (1) by 
converting bradykinin to a better agonist (des-arg-
bradykinin), and (2) by altering the conformation of the 
receptor on the membrane. Therefore, one can 
speculate that the functions of CPM are linked to the 
functions of bradykinin, e.g. release of inflammatory 
cytokines, vasodilation and pain. 
Homology 
CPM has significant homology with the M14B 
subfamily members CPN, CPH/E, CPZ, CPD, CPX-1, 




In the NCBI databases a number of variants can be 
found in the CPM genomic sequence that were reported 
in association studies related to blood pressure 
regulation and heart function (Vasan et al., 2007) and 
asthma and smoking (Litonjua et al., 2008; Pan et al., 





CPM gene amplification was detected in well-
differentiated liposarcomas but not in atypical 
lipomatous tumors. Using FISH and chromogenic in 
situ hybridization, amplification of the CPM gene was 
shown to discriminate well-differentiated liposarcoma 
from lipomas (Erickson-Johnson et al., 2009). These 
well-differentiated liposarcomas typically show 
telomeric associations, supernumerary ring 
chromosomes, and giant rod marker chromosomes.  
The abnormal chromosomes consist of amplified 
genomic sequences derived from chromosome bands 
12q13-15 and comprise several genes, including the 
MDM2 gene.  
MDM2/CPM amplification was proposed as a tool for 
classification of lipomatous tumors and evaluation of 
the impact of surgical procedures on the risk of local 
recurrence (Zhang et al., 2010). 
Clear cell lung carcinoma 
Note 
In lung adenocarcinoma, CPM and epidermal growth 
factor receptor (EGFR) protein expression appeared to 
be heterogeneous. CPM and EGFR were mainly 
restricted to tumor cell membranes. CPM expression 
was not limited to a specific histotype, and did not 
correlate with tumor grade nor stage.  
CPM negatively correlated with disease survival 
(Tsakiris et al., 2008). 80% of the CPM-positive 
adenocarcinoma were EGFR-positive. The coexistence 
of CPM and EGFR strongly predicted a poor outcome.  
An unfavourable role for CPM-EGFR co-expression 
was suggested in early tumor stages. Two cases of 
CPM--EGFR+ primary lung adenocarcinoma became 
CPM+-EGFR+ when metastasized to the brain, 
suggesting CPM is an inducible protein. 
Renal cell carcinoma 
Note 
Tumor cells of renal cell carcinoma subtypes lose CPM 
expression upon dedifferentiation. In a study of 7 clear 
cell renal carcinoma specimens and 1 chromophobe 
renal cell carcinoma CPM was colocalized with CD31 
(endothelium), vimentin (tumor marker) and CD68 
(macrophages) (Denis et al., 2013). Denis et al., 2013 
also studied coexpression of CPM and EGFR by 
immunohistochemistry using a tissue microarray 
containing 104 cases of various renal tumors and 
diseased renal tissue.  
An association between the CPM histology-score (H-
score) and tumor grade was observed for clear cell 
carcinoma. Cluster analysis of the CPM and EGFR H-
scores in this study showed coexisting high scores for 
CPM and EGFR only for papillary renal carcinoma.  
In papillary renal carcinoma expression of CPM is 
upregulated along with tumoral dedifferentiation. 
Molecular genetic analysis of papillary renal cell 
tumors revealed loss of the chromosome Y markers 
together with trisomy of chromosomes 3q, 7, 8, 12, 16, 
17 and 20. Trisomy of 12, 16 and 20 possibly are 
related to tumor progression. Allelic duplications were 
detected at the 12q12-14 chromosomal regions (to 
which the CPM gene maps), among others. 
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Adenocarcinoma 
Note 
Transcript analysis indicated that adenocarcinoma cells 
are positive for CPM (Ramaswamy et al., 2003). 
Endometrium and myometrium tumor 
tissue 
Note 
Transcript analysis indicated an upregulation of CPM 
compared to healthy tissue (Pessoa et al., 2002). 
Invasive ductal breast carcinoma 
Note 
Transcript analysis indicated an upregulation of CPM 
compared to healthy tissue (Overall et al., 2004). 
Clear cell ovarian cancer 
Note 
Transcript analysis indicated an upregulation of CPM 
compared to healthy tissue (Schwartz et al., 2002). 
Primary cutaneous squamous cell 
carcinoma 
Note 
Transcript analysis indicated an upregulation of CPM 
(Haider et al., 2006). 
Soft tissue carcinomas (synovial 




Transcript analysis indicated an upregulation of CPM 
(Francis et al., 2007). 
Lung cancer 
Note 
CPM activity was increased in bronchoalveolar lavage 
fluid of lung cancer patients (Dragovic et al., 1995). 
Rapidly growing hepatoma 
Note 
CPM activity was increased (Deddish et al., 1990). 
Pancreatic ductal adenocarcinoma 
Note 
Transcript analysis indicated an upregulation of CPM 
(Johnson et al., 2006). 
Small cell lung cancer 
Note 
Transcript analysis indicated a downregulation of CPM 
(Cohen et al., 1997). 
Leukemic mantle cell lymphoma 
Note 
Transcript analysis indicated a downregulation of CPM 
(Rizzatti et al., 2005). 
Primary breast cancer cells with 
complete response to therapy with 
gemcitabine, epirubicin and docetaxel 
Note 
Transcript analysis showed that these cells were 
positive for CPM (Thuerigen et al., 2006). 
Breakpoints 
Note 
The chromosome 12q13-15 bands were associated with 
a variety of benign and malignant solid tumor types by 
cytogenetic studies. Among the benign tumors, uterine 
leiomyoma, pleomorphic adenoma of the salivary 
gland, and lipoma all cluster to the 12q13-15 
chromosomal region, which is also involved in 
hemangiopericytoma, endometrial polyps, 
chondromatous tumors, pulmonary chondroid 
hamartoma, and in a number of cases of benign 
epithelial breast tumors, diffuse astrocytomas, and a 
giant-cell bone tumor. Recurrent aberrations in 12q13-
15 also have been detected in malignancies such as 
myxoid liposarcoma, soft tissue clear-cell sarcoma, 
chronic idiopathic myelofibrosis, and primary diffuse 
large B cell lymphomas. Using directional chromosome 
walking and uterine leiomyoma-derived cell lines, a 
breakpoint hot spot region was found at 12q13-15 
(named Uterine Leiomyoma Cluster Region on 
chromosome 12, ULCR12) (Schoenmakers et al., 
1994). Another breakpoint cluster region of 1.7 Mb was 
detected on chromosome 12q15 comprising the 
breakpoints of uterine leiomyoma, lipoma, and salivary 
gland adenoma cells (Van de Ven et al., 1995). This 
multiple-aberration region contains essentially all 
breakpoints of chromosome 12 (Wanshura et al., 1995). 
CPM was localized in the 12q15 region at one of the 
chromosomal breakpoints in radiation-transformed 
epithelial breast cell lines. Complex translocations were 
detected at this breakpoint. Since these gene 
rearrangements could alter CPM gene expression, CPM 
likely represents a breast cancer-involved candidate 
gene (Unger et al., 2010). EST analysis identified CPM 
as a putative fusion gene resulting from chromosome 
rearrangement. The ChimerDB database contains one 
instance where CPM acts as the 5' partner in a fusion 
gene (C7ORF64 7q21.2) and two instances where it is 
the 3' fusion partner (CYP19A1 15q21.1 and 
KIAA1737 14q24.3).  
The clinical consequences of these fusions are not 
known. 
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